CR20250087A - Inhibidores de kif18a y usos de estos - Google Patents
Inhibidores de kif18a y usos de estosInfo
- Publication number
- CR20250087A CR20250087A CR20250087A CR20250087A CR20250087A CR 20250087 A CR20250087 A CR 20250087A CR 20250087 A CR20250087 A CR 20250087A CR 20250087 A CR20250087 A CR 20250087A CR 20250087 A CR20250087 A CR 20250087A
- Authority
- CR
- Costa Rica
- Prior art keywords
- kif18a
- inhibitors
- inhibition
- cancer
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
- C07F7/0816—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring comprising Si as a ring atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se proporcionan compuestos de Fórmula (I): <img src="data:image/png;base64,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 (***)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263399003P | 2022-08-18 | 2022-08-18 | |
| US202363463617P | 2023-05-03 | 2023-05-03 | |
| PCT/US2023/030544 WO2024039829A1 (en) | 2022-08-18 | 2023-08-18 | Inhibitors of kif18a and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20250087A true CR20250087A (es) | 2025-07-11 |
Family
ID=88068723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20250087A CR20250087A (es) | 2022-08-18 | 2023-08-18 | Inhibidores de kif18a y usos de estos |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20260062430A1 (es) |
| EP (1) | EP4572855A1 (es) |
| JP (1) | JP2025529821A (es) |
| KR (1) | KR20250078442A (es) |
| CN (1) | CN120187733A (es) |
| AU (1) | AU2023324826A1 (es) |
| CA (1) | CA3264917A1 (es) |
| CL (1) | CL2025000445A1 (es) |
| CO (1) | CO2025003263A2 (es) |
| CR (1) | CR20250087A (es) |
| JO (1) | JOP20250036A1 (es) |
| MX (1) | MX2025001982A (es) |
| PE (1) | PE20251601A1 (es) |
| TW (1) | TW202416973A (es) |
| WO (1) | WO2024039829A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL283639B2 (en) | 2018-12-20 | 2024-06-01 | Amgen Inc | Kif18a inhibitors |
| CR20250087A (es) | 2022-08-18 | 2025-07-11 | Accent Therapeutics Inc | Inhibidores de kif18a y usos de estos |
| CN121100117A (zh) * | 2023-05-16 | 2025-12-09 | 浙江海正药业股份有限公司 | 芳香酰胺类衍生物、其制备方法和其在医药上的应用 |
| CN121693499A (zh) * | 2023-08-16 | 2026-03-17 | 上海湃隆生物科技有限公司 | 驱动蛋白kif18a抑制剂及其应用 |
| CN119504636B (zh) * | 2024-11-25 | 2026-03-13 | 上海筛杰生物医药有限公司 | 一种2-（4-氟苯基）-6-硝基-4-（2,2,2-三氟乙氧基）-1,2-苯并噻唑-3-酮的制备方法及其中间体和应用 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019404576B2 (en) * | 2018-12-20 | 2025-07-17 | Amgen Inc. | Heteroaryl amides useful as KIF18A inhibitors |
| IL283639B2 (en) * | 2018-12-20 | 2024-06-01 | Amgen Inc | Kif18a inhibitors |
| MA54550A (fr) * | 2018-12-20 | 2022-03-30 | Amgen Inc | Inhibiteurs de kif18a |
| AU2019401495B2 (en) * | 2018-12-20 | 2025-06-26 | Amgen Inc. | Heteroaryl amides useful as KIF18A inhibitors |
| MX428368B (es) | 2019-08-02 | 2025-11-13 | Amgen Inc | Inhibidores de kif18a |
| AU2020325115B2 (en) * | 2019-08-02 | 2026-03-12 | Amgen Inc. | Pyridine derivatives as KIF18A inhibitors |
| US20220289724A1 (en) * | 2019-08-02 | 2022-09-15 | Amgen Inc. | Kif18a inhibitors |
| JP7699100B2 (ja) * | 2019-08-02 | 2025-06-26 | アムジエン・インコーポレーテツド | Ｋｉｆ１８ａ阻害剤 |
| JP2023521802A (ja) | 2020-04-14 | 2023-05-25 | アムジエン・インコーポレーテツド | 新生物疾患の処置のためのｋｉｆ１８ａ阻害剤 |
| WO2021231413A1 (en) | 2020-05-11 | 2021-11-18 | University Of Vermont | A treatment approach involving kif18a inhibition for chromosomally unstable tumors |
| EP4361142A4 (en) | 2021-06-25 | 2025-07-09 | Hangzhou Innogate Pharma Co Ltd | COMPOUND FOR USE AS A KIF18A INHIBITOR |
| TW202321213A (zh) | 2021-07-21 | 2023-06-01 | 美商安進公司 | Ｋｉｆ１８ａ抑制劑化合物之鹽和固態形式 |
| KR20240109977A (ko) | 2021-08-26 | 2024-07-12 | 볼라스트라 쎄라퓨틱스, 인코포레이티드 | Kif18a의 스피로 인돌린 억제제 |
| CN115772159A (zh) | 2021-09-06 | 2023-03-10 | 微境生物医药科技(上海)有限公司 | Kif18a抑制剂 |
| CN115785068A (zh) | 2021-09-10 | 2023-03-14 | 微境生物医药科技(上海)有限公司 | Kif18a抑制剂 |
| CN118076586A (zh) | 2021-09-16 | 2024-05-24 | 微境生物医药科技(上海)有限公司 | Kif18a抑制剂 |
| US20240428939A1 (en) | 2021-09-22 | 2024-12-26 | Volastra Therapeutics, Inc. | Systems and methods for evaluation of mitotic events using machine-learning |
| MX2024005996A (es) | 2021-11-19 | 2024-05-30 | Wigen Biomedicine Tech Shanghai Co Ltd | Inhibidor de kif18a. |
| AU2023211589A1 (en) | 2022-01-26 | 2024-07-25 | Amgen Inc. | Synthesis of a kif18a inhibitor |
| CN118613478A (zh) | 2022-03-17 | 2024-09-06 | 微境生物医药科技(上海)有限公司 | Kif18a抑制剂 |
| AU2023254325B2 (en) | 2022-04-15 | 2026-06-04 | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | Kif18a inhibitor and use thereof |
| CN116925065A (zh) | 2022-04-22 | 2023-10-24 | 武汉人福创新药物研发中心有限公司 | 抑制kif18a的化合物及用途 |
| AU2023261964A1 (en) | 2022-04-28 | 2024-11-07 | Volastra Therapeutics, Inc. | Compounds for inhibiting kif18a |
| WO2023212714A1 (en) | 2022-04-29 | 2023-11-02 | Amgen Inc. | Kif18a inhibition for treatment of cancer |
| EP4524136A4 (en) | 2022-05-13 | 2025-08-06 | Shanghai Apeiron Therapeutics Company Ltd | KINESIN INHIBITOR KIF18A AND ITS USE |
| CN116789637B (zh) | 2022-05-13 | 2024-08-02 | 上海湃隆生物科技有限公司 | 驱动蛋白kif18a抑制剂及其应用 |
| CN117069694A (zh) | 2022-05-17 | 2023-11-17 | 武汉人福创新药物研发中心有限公司 | Kif18a的抑制剂及其用途 |
| US20250382298A1 (en) | 2022-06-30 | 2025-12-18 | Suzhou Genhouse Bio Co., Ltd. | Nitrogen-containing compound and use thereof |
| WO2024022508A1 (zh) | 2022-07-29 | 2024-02-01 | 武汉人福创新药物研发中心有限公司 | Kif18a抑制剂及用途 |
| CN117510463B (zh) | 2022-08-05 | 2026-05-29 | 长春金赛药业有限责任公司 | Kif18a抑制剂化合物、药物组合物及其制备方法和应用 |
| WO2024032661A1 (zh) | 2022-08-11 | 2024-02-15 | 山东轩竹医药科技有限公司 | Kif18a抑制剂及其用途 |
| CR20250087A (es) | 2022-08-18 | 2025-07-11 | Accent Therapeutics Inc | Inhibidores de kif18a y usos de estos |
| AU2023337160A1 (en) | 2022-09-08 | 2025-03-20 | Changchun Genescience Pharmaceutical Co., Ltd. | Kif18a inhibitor compound, and pharmaceutical composition and preparation method therefor and use thereof |
| WO2024051812A1 (zh) | 2022-09-09 | 2024-03-14 | 先声再明医药有限公司 | 酰胺类化合物、其组合物及用途 |
| CN117683017A (zh) | 2022-09-09 | 2024-03-12 | 先声再明医药有限公司 | 芳酰胺类化合物、其组合物及用途 |
| CN119072473B (zh) | 2022-09-30 | 2026-05-29 | 长春金赛药业有限责任公司 | 稠环类kif18a抑制剂化合物、药物组合物及其制备方法和应用 |
| WO2024067465A1 (zh) | 2022-09-30 | 2024-04-04 | 山东轩竹医药科技有限公司 | Kif18a抑制剂 |
| CN119894878A (zh) | 2022-10-13 | 2025-04-25 | 浙江海正药业股份有限公司 | 芳香酰胺类衍生物及其制备方法和用途 |
| CN120092002A (zh) | 2022-10-19 | 2025-06-03 | 海南先声再明医药股份有限公司 | 稠合杂芳烃类化合物、其组合物及用途 |
| CN117917405A (zh) | 2022-10-21 | 2024-04-23 | 杭州邦顺制药有限公司 | Kif18a蛋白抑制剂 |
| JP2025538601A (ja) | 2022-11-24 | 2025-11-28 | インベンティスバイオ カンパニー リミテッド | 複素環化合物、その製造方法および用途 |
| CN115594664B (zh) | 2022-11-25 | 2023-02-24 | 英矽智能科技(上海)有限公司 | 一类螺环衍生物作为kif18a抑制剂 |
| WO2024114730A1 (zh) | 2022-11-30 | 2024-06-06 | 微境生物医药科技(上海)有限公司 | 一种用于癌症治疗的药物组合物 |
| JP2026508745A (ja) | 2022-12-02 | 2026-03-12 | シェンチェン ジョングァー バイオロジカル テクノロジー カンパニー リミテッド | アミド又はウレア系化合物 |
| CN120265626A (zh) | 2022-12-14 | 2025-07-04 | 浙江海正药业股份有限公司 | 芳香酰胺类衍生物、其制备方法和其在医药上的应用 |
| CN120641408A (zh) | 2022-12-16 | 2025-09-12 | 抟相医药(上海)有限公司 | 含氮化合物、药物组合物及其用途 |
| KR20250121432A (ko) | 2022-12-21 | 2025-08-12 | 암젠 인크 | Mta-협력 prmt5 저해제를 사용한 암 치료 |
| US20260209248A1 (en) | 2022-12-28 | 2026-07-23 | Insilico Medicine Ip Limited | Inhibitors of kif18a and uses thereof |
| CN120569373A (zh) | 2023-01-05 | 2025-08-29 | 浙江海正药业股份有限公司 | 芳香酰胺类衍生物及其制备方法和医药上的用途 |
| WO2024149189A1 (zh) | 2023-01-09 | 2024-07-18 | 浙江海正药业股份有限公司 | 芳香酰胺类衍生物及其制备方法和用途 |
| TW202434237A (zh) | 2023-01-20 | 2024-09-01 | 香港商英矽智能科技知識產權有限公司 | Kif18a之抑制劑及其用途 |
| CN116199636A (zh) | 2023-02-21 | 2023-06-02 | 杭州医学院 | 靶向肿瘤免疫激酶的2,4-二取代嘧啶衍生物、制备方法及其应用 |
| AU2024226158A1 (en) | 2023-02-23 | 2025-08-14 | Volastra Therapeutics, Inc. | Solid formulations and polymorphic forms of indoline inhibitors of kif18a |
| CN121002013A (zh) | 2023-04-18 | 2025-11-21 | 南京同诺康医药科技有限公司 | Kif18a抑制剂及其制备方法和用途 |
| CN116535400B (zh) | 2023-04-26 | 2024-08-16 | 上海湃隆生物科技有限公司 | 氮杂螺环化合物及其应用 |
| CN121100117A (zh) | 2023-05-16 | 2025-12-09 | 浙江海正药业股份有限公司 | 芳香酰胺类衍生物、其制备方法和其在医药上的应用 |
| WO2024244972A1 (zh) | 2023-05-30 | 2024-12-05 | 浙江海正药业股份有限公司 | 芳香酰胺类衍生物及其制备方法和用途 |
| AU2024305256A1 (en) | 2023-06-14 | 2026-01-15 | Volastra Therapeutics, Inc. | Method of treating cancer with indoline inhibitors of kif18a |
| EP4735420A1 (en) | 2023-06-29 | 2026-05-06 | Volastra Therapeutics, Inc. | Aryl indol-3-yl ketone and aryl indazol-3-yl ketone inhibitors of kif18a |
-
2023
- 2023-08-18 CR CR20250087A patent/CR20250087A/es unknown
- 2023-08-18 PE PE2025000401A patent/PE20251601A1/es unknown
- 2023-08-18 US US19/103,998 patent/US20260062430A1/en active Pending
- 2023-08-18 CA CA3264917A patent/CA3264917A1/en active Pending
- 2023-08-18 KR KR1020257008820A patent/KR20250078442A/ko active Pending
- 2023-08-18 EP EP23772003.2A patent/EP4572855A1/en active Pending
- 2023-08-18 CN CN202380068844.7A patent/CN120187733A/zh active Pending
- 2023-08-18 WO PCT/US2023/030544 patent/WO2024039829A1/en not_active Ceased
- 2023-08-18 TW TW112131231A patent/TW202416973A/zh unknown
- 2023-08-18 AU AU2023324826A patent/AU2023324826A1/en active Pending
- 2023-08-18 JP JP2025509109A patent/JP2025529821A/ja active Pending
-
2025
- 2025-01-14 US US19/020,085 patent/US12391709B2/en active Active
- 2025-02-12 JO JOJO/P/2025/0036A patent/JOP20250036A1/ar unknown
- 2025-02-17 CL CL2025000445A patent/CL2025000445A1/es unknown
- 2025-02-17 MX MX2025001982A patent/MX2025001982A/es unknown
- 2025-03-13 CO CONC2025/0003263A patent/CO2025003263A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250078442A (ko) | 2025-06-02 |
| US12391709B2 (en) | 2025-08-19 |
| MX2025001982A (es) | 2025-04-02 |
| TW202416973A (zh) | 2024-05-01 |
| CL2025000445A1 (es) | 2025-09-05 |
| JOP20250036A1 (ar) | 2025-02-12 |
| US20250197428A1 (en) | 2025-06-19 |
| WO2024039829A1 (en) | 2024-02-22 |
| EP4572855A1 (en) | 2025-06-25 |
| AU2023324826A1 (en) | 2025-02-27 |
| CA3264917A1 (en) | 2024-02-22 |
| CN120187733A (zh) | 2025-06-20 |
| US20260062430A1 (en) | 2026-03-05 |
| CO2025003263A2 (es) | 2025-06-06 |
| JP2025529821A (ja) | 2025-09-09 |
| PE20251601A1 (es) | 2025-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| MX2025001982A (es) | Inhibidores de kif18a y usos de estos | |
| JOP20240181A1 (ar) | مثبطات هيليكاز الـ rna dhx9 واستخداماتها | |
| MX2024001893A (es) | Compuestos heterociclicos y metodos de uso. | |
| MX2023012726A (es) | Compuestos heterociclicos y metodos de uso. | |
| PH12020551717A1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| MX2025002170A (es) | Inhibidores de kras g12c | |
| MX2026003002A (es) | Inhibidores de kras | |
| MX2025011447A (es) | Inhibidores de kras | |
| MX2022013482A (es) | Compuestos utiles para inhibir la quinasa ret. | |
| MX2021013993A (es) | Pirroles triciclicos condensados como moduladores de alfa-1 antitripsina. | |
| MX2023010411A (es) | Inhibidores de erbb/btk. | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| MX2020010942A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| PH12022551858A1 (en) | Novel heterocyclic compounds useful as aurora a selective inhibitors | |
| ZA202401684B (en) | Novel parp7 inhibitor and use thereof | |
| MX2021010321A (es) | Compuestos macrociclicos. | |
| WO2022240971A3 (en) | Kras g12d inhibitors and uses thereof | |
| MX393711B (es) | Derivados de tiocarbamato como inhibidores de a2a y metodos para su uso en el tratamiento de canceres | |
| MX2022009197A (es) | Metodos de tratamiento para deficiencia de alfa-1 antitripsina. | |
| MX2023013715A (es) | Regímenes de dosis de ecubectedina. | |
| MX2024013095A (es) | Compuestos inhibidores de fgfr2 | |
| WO2025038462A3 (en) | Inhibitors of rna helicase dhx9 and uses thereof | |
| MX2025013436A (es) | Derivados de carboxamida heteroaromatica como inhibidores de la calicreina plasmatica | |
| UA96969C2 (en) | Acylaminopyrazoles as fgfr inhibitors |